INSIGHTS ON DRUG DEVELOPMENT

  • AI Enabled Pharmaceutical Cocrystal Screening
    9/3/2026

    Cocrystal candidate screening is resource-intensive and prone to gaps. This paper examines how AI-based modeling, trained on more than 20,000 data points, can sharpen candidate prioritization without sacrificing scientific rigor.

  • Alzheimer's Disease Pathway
    3/24/2025

    Alzheimer’s disease (AD) affects 50 million people globally, causing cognitive decline. Explore the signaling pathways of amyloid beta and tau proteins, linking them to neuronal death and AD symptoms.

  • How To Benchmark Your Digital Transformation Performance And AI-Readiness
    6/18/2026

    AI investment is rising across life sciences, but data challenges stall real-world adoption. Discover what is holding teams back and how to turn AI potential into practical scientific impact.

  • Assessing Viability And Real-Time Apoptosis/Necrosis
    3/17/2025

    Malignant gliomas are aggressive brain tumors that resist standard treatments. Discover why researchers focus on real-time cell death dynamics to develop targeted therapies and promising strategies.

  • Easy Automation For Cell-Based Assays
    10/10/2025

    Automated GPCR screening is now faster and more scalable with integrated cell-based assay solutions. Discover how combining high-throughput platforms with flexible assay kits can streamline workflows.

DRUG DEVELOPMENT SOLUTIONS